Novo Nordisk’s weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly’s Zepbound, and now the ...

NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.

Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...

Ozempic and Wegovy maker Novo ... hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has ...

The company behind popular new drug Ozempic says its CEO ... in value since June last year amid intensifying competition in the obesity drug market. The CEO of Danish pharmaceutical giant Novo ...

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels ...

Danish pharmaceutical giant Novo Nordisk is saying goodbye to its chief executive amid growing competition for its blockbuster weight loss drugs Wegovy and Ozempic.

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday its chief executive was stepping down in the wake of "market challenges".

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market has grown fiercer. By Rebecca Robbins Novo Nordisk will replace its ...

India's healthtech space is expected to witness disruption as weight loss drugs Ozempic and Mounjaro enter the market through ...

This one-time weight-loss drug leader has suffered several setbacks lately. It isn't wise to count out this veteran ...